Episode Details
Back to Episodes
Ep 46: Ideaya’s eye cancer drug met its phase 2/3 primary endpoint, clearing a path to accelerated FDA filing later this year.
Season 1
Episode 46
Published 2 months ago
Description
**HOOK:** Ideaya’s eye cancer drug met its phase 2/3 primary endpoint, clearing a path to accelerated FDA filing later this year.
━━━━━━━━━━━━━━━━━━━━
### Top 15 Science & Health Discoveries
1. **Eye Cancer Drug Hits Phase 2/3 Goal: 15 Apr 2026 • Fierce Biotech**
Ideaya Biosciences and Servier’s candidate has succeeded in its phase 2/3 trial for a form of eye cancer. The result positions the companies to submit for accelerated FDA approval in the second half of 2026. ...
AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis (ElevenLabs) for audio production.